Hem › Bröstcancer › Arizona › Scottsdale
Kliniska studier för Bröstcancer i Scottsdale, AZ
18 studier för Bröstcancer söker deltagare vid platser i och runt Scottsdale (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
RekryterarFas 2
- Mayo Clinic, Scottsdale
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
RekryterarFas 3
- Mayo Clinic, Scottsdale
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
RekryterarFas 3
- Ironwood Cancer & Research Centers, Scottsdale
Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer
RekryterarFas 2
- Mayo Clinic in Arizona, Scottsdale
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Rekryterar
- Honor Health Research Institute, Scottsdale
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RekryterarFas 3
- Mayo Clinic, Scottsdale
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
RekryterarFas 1
- Mayo Clinic of Scottsdale, Scottsdale
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RekryterarFas 1
- HonorHealth, Scottsdale
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RekryterarFas 2
- Mayo Clinic in Arizona, Scottsdale
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RekryterarFas 1
- HonorHealth Research Institute, Scottsdale
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
RekryterarFas 2
- Mayo Clinic in Arizona, Scottsdale
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
RekryterarFas 3
- Mayo Clinic - Scottsdale, Scottsdale
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekryterarFas 2
- Mayo Clinic - Scottsdale, Scottsdale
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RekryterarFas 3
- Ironwood Cancer & Research Centers, Scottsdale
Cancer Genetic Testing in Ethnic Populations
Rekryterar
- Mayo Clinic in Arizona, Scottsdale
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RekryterarFas 1
- HonorHealth Research Institute, Scottsdale
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RekryterarFas 4
- Scottsdale Medical Imaging, LLC, Scottsdale
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Scottsdale
Bröstcancer-studier i andra städer
- New York City, NY136 studier
- Houston, TX126 studier
- Boston, MA112 studier
- Nashville, TN81 studier
- Los Angeles, CA73 studier
- Edison, NJ68 studier
- St. Louis, MO64 studier
- Queens, NY64 studier
- Durham, NC64 studier
- Chicago, IL59 studier
- Philadelphia, PA56 studier
- Dallas, TX55 studier
Andra studier i Scottsdale
- Cancer (alla typer)18 studier
- Metastaserande cancer17 studier
- Prostatacancer17 studier
- Kolorektal cancer16 studier
- Icke-småcellig lungcancer15 studier
- Bukspottkörtelcancer13 studier
- Melanom10 studier
- Ulcerös kolit8 studier
- Lungcancer8 studier
- Levercancer (hepatocellulärt karcinom)7 studier
- Alzheimers sjukdom7 studier
- Triplenegativ bröstcancer7 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.